Academic Journal
OP76 Cost-Effectiveness Of Offering Human Papillomavirus Self-Sampling To Non-Attendees Of Organized Primary Cervical Cancer Screening In Germany
| العنوان: | OP76 Cost-Effectiveness Of Offering Human Papillomavirus Self-Sampling To Non-Attendees Of Organized Primary Cervical Cancer Screening In Germany |
|---|---|
| المؤلفون: | Sroczynski, Gaby, Hallsson, Lára R., Muehler, Milena, Hillemanns, Peter, Jentschke, Matthias, Siebert, Uwe |
| المصدر: | International Journal of Technology Assessment in Health Care ; volume 40, issue S1, page S34-S34 ; ISSN 0266-4623 1471-6348 |
| بيانات النشر: | Cambridge University Press (CUP) |
| سنة النشر: | 2024 |
| الوصف: | Introduction In Germany, organized cervical cancer screening with annual Papanicolaou (Pap) cytology for women age 20 to 34 years and three-yearly co-testing with human papillomavirus (HPV) and Pap for women as of age 35 years is standard. However, about 30 percent of women eligible for screening remain un/under-screened. We systematically evaluated benefits, risks, and cost-effectiveness of offering additional HPV self-sampling (HPV-SS) to non-attendees. Methods A validated Markov model for the German context was used to evaluate different HPV-SS screening strategies compared to standard clinician-based screening: HPV-SS for non-attendees age 25 to 65, 30 to 65 or 35 to 65 years, every five years with regular invitation, either opt-in (invitation with link to order the test), or send-to-all (test sent with invitation). German clinical, epidemiological, and economic data (index year 2022/23), along with test accuracy and HPV-SS-attendance data from international meta-analyses and trials were incorporated. Outcomes included undiscounted life years gained (LYG) compared to standard screening without HPV-SS in non-attendees, and the incremental cost-effectiveness ratio (ICER; in EUR/LYG). Comprehensive sensitivity analyses were performed. Results Incremental undiscounted effectiveness (compared to standard screening without HPV-SS) and discounted ICERs (compared to next effective) for non-dominated HPV-SS screening strategies were 0.00090 LYG (EUR22,700/LYG) for offering with five-yearly screening invitation an HPV-SS (opt-in) to non-attendees age 35 to 65, 0.00166 LYG (EUR25,900/LYG) for HPV-SS (send-to-all) age 35 to 65, 0.00167 (EUR726,000/LYG) for HPV-SS (send-to-all) age 30 to 65, and 0.00167 LYG (EUR1.78 million/LYG) for HPV-SS (send-to-all) age 25 to 65 years. Other opt-in strategies were dominated. Results were robust over a wide range of parameter variations. Conclusions Offering HPV-SS (send-to-all) to non-attendees every five years as an additional strategy within the organized cervical cancer screening ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1017/s0266462324001351 |
| الاتاحة: | https://doi.org/10.1017/s0266462324001351 https://www.cambridge.org/core/services/aop-cambridge-core/content/view/S0266462324001351 |
| Rights: | https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.3FC900E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1017/s0266462324001351 |
|---|